Xanthus' Symadex(TM) shows Remyelination in Multiple Sclerosis Animal Model

- Results Presented at the International Workshop on Myelin Imaging in

Vancouver -

Feb 13, 2006, 00:00 ET from Xanthus Life Sciences, Inc.

    CAMBRIDGE, Mass., Feb. 13 /PRNewswire/ -- Xanthus Life Sciences, Inc.,
 today announced that data from a study conducted with a Multiple Sclerosis
 (MS) animal model demonstrated that Symadex(TM) permitted remyelination by
 prevention of inflammatory cell infiltration. Stephen J. Karlik, Ph.D.,
 Professor of Diagnostic Radiology at the University of Western Ontario,
 London, Ontario presented the research findings on February 10, 2006 at the
 International Workshop on Myelin Imaging, in Vancouver.
     Dr. Karlik is widely recognized for investigating potential new therapies
 for MS in a specialized animal model of human MS that incorporates both
 inflammatory and demyelinating properties.  Symadex was found to produce
 remyelination in the study even after 40 days of inflammatory insult by
 preventing the infiltration of autoreactive cells into the central nervous
 system.  Treatment proved to be effective in both the acute and chronic
 presentations of disease.
     "The early results from this study showed that the animals in the study,
 which were paralyzed due to neurological impairment, were able  to recover and
 regain their mobility after treatment with Symadex," commented Dr. Karlik.
     "Symadex is now in Phase 2 trials in oncology and the positive results of
 this animal model study show the candidate's potential for treating MS and
 provide the support needed to advance Symadex towards human trials for MS,"
 said Michael A. Boss, PhD. Chief Business Officer at Xanthus.
     About Symadex(TM)
     Symadex (formerly C-1311) is a next-generation investigational drug that
 has shown a potentially novel, targeted mechanism of action in studies of
 cancer and autoimmune disease.  Symadex was developed to deliver efficacy
 comparable to the anthracenediones (e.g., Novantrone(R) (mitoxantrone)), but
 with a molecular scaffold intended to reduce the cardio- and hemato-toxicities
 known to be associated with these active drugs.  Additionally, in previous
 preclinical studies, Symadex has shown early evidence of both oral activity
 and efficacy in various models of acquired drug resistance and autoimmune
 disease.  The Company is conducting Phase 2 clinical trials with Symadex in
 several tumor indications and is also exploring the use of Symadex for the
 treatment of a number of autoimmune diseases, such as Multiple Sclerosis.
     About Multiple Sclerosis
     Multiple Sclerosis (MS) is a chronic, unpredictable disease of the central
 nervous system that, according to the National MS Society, affects
 approximately 400,000 people in the United States and approximately 2.5
 million people worldwide.  It is a disease typically of young adults, mostly
 women, with onset typically between 20 and 50 years of age. Each hour someone
 is newly diagnosed. MS symptoms may include vision problems, loss of balance,
 numbness, difficulty walking and even complete paralysis.
     About Xanthus Life Sciences, Inc.
     Xanthus Life Sciences, Inc. is developing a portfolio of novel, clinical-
 stage, small-molecule oncology drugs through a management team whose
 accomplished track record encompasses all aspects of drug development, from
 discovery through regulatory approval and commercialization.  The Company is
 applying its expertise both to advance its current pipeline and expand it into
 indications of unmet medical need beyond oncology.
     Xanthus is headquartered in Cambridge, Massachusetts with an additional
 facility in Montreal, Quebec. More information is available at www.xanthus.com.
     This press release contains forward-looking statements concerning Xanthus
 that involve a number of risks and uncertainties. For this purpose, any
 statements contained herein that are not statements of historical fact may be
 deemed to be forward-looking statements. Without limiting the foregoing, the
 words, "believes," "anticipates," "plans," "expects," "estimates," "intends,"
 "should," "could," "will," "may," and similar expressions are intended to
 identify forward-looking statements. There are a number of important factors
 that could cause Xanthus' actual results to differ materially from those
 indicated by such forward-looking statements, including risks as to whether
 results obtained in early clinical studies or in preclinical studies such as
 the studies referred to above will be indicative of results obtained in future
 clinical trials or warrant additional trials; whether products based on
 Xanthus' technology will advance through the clinical trial process and
 receive approval from the United States Food and Drug Administration or
 equivalent foreign regulatory agencies; whether the company will have the cash
 resources to develop and commercialize its products; and whether the patent
 and patent applications owned or licensed by Xanthus will protect the
 Company's technology and prevent others from infringing it.  Xanthus disclaims
 any intention or obligation to update any forward-looking statements.
     Kari Watson, MacDougall Biomedical Communications, Inc. -
     kwatson@macbiocom.com or (508) 647-0209
     John A. McCarthy, Jr., Senior Vice President & CFO, Xanthus Life Sciences,
     Inc. - john.mccarthy@xanthus.com or (617) 225-0522, x 125

SOURCE Xanthus Life Sciences, Inc.